RESUMEN
OBJECTIVE:To investigate clinical efficacy and safety of oral loratadine combined with physiological seawater na-sal irrigation in the treatment of intermittent allergic rhinitis. METHODS:Totally 300 patients with intermittent allergic rhinitis were chosen from the Second Hospital of Hebei Medical University during Jan. 2013-Jun. 2015,and then divided into group A,B,C ac-cording to lottery method,with 100 cases in each group. Group A was given Loratadine tablets 10 mg,po,qd. Group B received nasal irrigation with physiological seawater nasal spray,every morning and evening. Group C was given oral loratadine combined with physiological seawater nasal irrigation. Treatment courses of 3 groups lasted for 28 d. Clinical efficiencies of 3 groups were compared as well as symptom and sign scores,respiration function indexes and inflammatory factor levels before and after treat-ment,and the clinical recurrences were followed up for 12 months. RESULTS:The total response rates of group A,B,C were 80.00%,78.00%,96.00%,respectively,and that of group C was significantly higher than that of group A and B,with statistical significance(P0.05). After treatment,symptom and sign scores,the rates of PEF diur-nal variation,TNF-α,INF-γ and IL-4 in 3 groups were significantly lower than before treatment,and the levels of PEF and IL-12 were significantly higher than before treatment. Above indexes of group C were significantly better than those of group A and B, with statistical significance (P0.05). CONCLUSIONS:Oral loratadine combined with physiological seawater nasal irrigation in treatment of intermittent allergic rhinitis can efficiently relieve the nasal symptoms and signs,improve expiratoryfunction,reduce the inflammatory response levels and be help-ful to reduce the long-term recurrence risk.
RESUMEN
OBJECTIVE@#To study the effect of intranasal glucosteroid on the expression of PKC, Bcl-2 and Bax in nasal polyps.@*METHOD@#The expression of PKC, Bcl-2 protein and Bax were detected with immunohistochemistry in nasal polyps from the patients (n=16) pre and post treated for 4 weeks with intranasal glucosteroid. And which compared with normal mucous membrane of inferior turbinate concha.@*RESULT@#The PKC and Bcl-2 protein expressed significantly higher in the pretreated patients (P < 0.01), which were significant reduced in the post treated patients compared with pretreated ones. The expression of Bax protein significantly higher in the post treated patients (P < 0.05).@*CONCLUSION@#Our findings indicated that abnormal expression of apoptosis related genes in nasal polyps tissues might play an important role in the occurrence and progression of nasal polyps. The treatment of intranasal glucosteroid may regulate the expression of apoptosis related genes.
Asunto(s)
Adolescente , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Administración Intranasal , Glucocorticoides , Farmacología , Usos Terapéuticos , Pólipos Nasales , Quimioterapia , Metabolismo , Proteína Quinasa C , Metabolismo , Proteínas Proto-Oncogénicas c-bcl-2 , Metabolismo , Proteína X Asociada a bcl-2 , MetabolismoRESUMEN
OBJECTIVE To observe the effect s of local corticosteroids on the expression of Eotaxin in nasal polyps and the mechanism of corticosteroids in the treatment of nasal polyps.METHODS The SP immunohistochemical method was used to detect the expression of Eotaxin in nasal polyps before and after treatment with corticosteroids.RESULTS The protein level of eotaxin significantly increased in the nasal polyps compared to the control tissues(P
RESUMEN
Objective To study the changes of AT-III and PAI-1 in the blood of patients with sudden sensorineural hearing loss(SSHL) and investigate the relationship between their levels and the disease.Methods The levels of AT-III and PAI-1 in the blood of 44 patients with SSHL and 30 healthy volunteers were detected using chromogentic substrate method.Results The changes of AT-III and PAI-1 in the blood of patients with SSHL were correlated with the process of the disease.There was significant difference between the levels of AT-III and PAI-1 in the blood of patients within 3 days and that of patients beyond 1 week(P